BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30076176)

  • 1. Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.
    De Smedt R; Peirs S; Morscio J; Matthijssens F; Roels J; Reunes L; Lintermans B; Goossens S; Lammens T; Van Roy N; Touzart A; Jenni S; Tsai YC; Lovisa F; Mussolin L; Serafin V; Van Nieuwerburgh F; Deforce D; Uyttebroeck A; Tousseyn T; Burkhardt B; Klapper W; De Moerloose B; Benoit Y; Macintyre E; Bourquin JP; Basso G; Accordi B; Bornhauser B; Meijerink J; Vandenberghe P; Van Vlierberghe P
    Haematologica; 2019 Jan; 104(1):e17-e20. PubMed ID: 30076176
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
    Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
    Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
    Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
    Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
    Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
    Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
    More KN; Hong VS; Lee A; Park J; Kim S; Lee J
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2513-2517. PubMed ID: 29871845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.
    Bellon M; Lu L; Nicot C
    Blood; 2016 May; 127(20):2439-50. PubMed ID: 26813676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
    De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
    Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pim kinase inhibitory and antiproliferative activity of a novel series of meridianin C derivatives.
    More KN; Jang HW; Hong VS; Lee J
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2424-8. PubMed ID: 24775304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
    Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
    Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations.
    Marques MB; González-Durruthy M; da Silva Nornberg BF; Oliveira BR; Almeida DV; de Souza Votto AP; Marins LF
    Curr Top Med Chem; 2019; 19(11):914-926. PubMed ID: 31072293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors - Lead optimization - Part III.
    Barberis C; Pribish J; Tserlin E; Gross A; Czekaj M; Barragué M; Erdman P; Maniar S; Jiang J; Fire L; Patel V; Hebert A; Levit M; Wang A; Sun F; Huang SA
    Bioorg Med Chem Lett; 2019 Feb; 29(3):491-495. PubMed ID: 30553737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of new thieno[2,3-b]pyridine derivatives as pim-1 inhibitors.
    Naguib BH; El-Nassan HB
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1718-25. PubMed ID: 27541740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
    Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
    Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and identification of PIM-1 kinase inhibitors through a hybrid screening approach.
    Shao M; Yuan Y; Yu K; Lei K; Zhu G; Chen L; Xiang M
    Mol Divers; 2014 May; 18(2):335-44. PubMed ID: 24519385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
    Martínez-González S; Rodríguez-Arístegui S; Gómez de la Oliva CA; Hernández AI; González Cantalapiedra E; Varela C; García AB; Rabal O; Oyarzabal J; Bischoff JR; Klett J; Albarrán MI; Cebriá A; Ajenjo N; García-Serelde B; Gómez-Casero E; Cuadrado-Urbano M; Cebrián D; Blanco-Aparicio C; Pastor J
    Eur J Med Chem; 2019 Apr; 168():87-109. PubMed ID: 30802730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of new pyridothienopyrimidinone and pyridothienotriazolopyrimidine derivatives as pim-1 inhibitors.
    El-Nassan HB; Naguib BH; Beshay EA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):58-66. PubMed ID: 29161928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and docking study of pyridine and thieno[2,3-b] pyridine derivatives as anticancer PIM-1 kinase inhibitors.
    Abdelaziz ME; El-Miligy MMM; Fahmy SM; Mahran MA; Hazzaa AA
    Bioorg Chem; 2018 Oct; 80():674-692. PubMed ID: 30064079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and Pim-1 kinase inhibitors.
    Li K; Li Y; Zhou D; Fan Y; Guo H; Ma T; Wen J; Liu D; Zhao L
    Bioorg Med Chem; 2016 Apr; 24(8):1889-97. PubMed ID: 26979485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I.
    Barberis C; Moorcroft N; Arendt C; Levit M; Moreno-Mazza S; Batchelor J; Mechin I; Majid T
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4730-4734. PubMed ID: 28947155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.